Sept. 18, 2008 –SYGNIS Pharma AG today announced that it has received a positive recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) for AX200 in the treatment of spinal cord injury.
The details can be read here.
No comments:
Post a Comment